Latest Posts

February 5, 2021 - PathGroup is pleased to announce the availability of a new serologic test for the detection of human antibodies to the SARS-CoV-2 spike protein (S) receptor binding domain (RBD), the viral pathogen associated with SARS-CoV-2 (COVID-19). The Roche Elecsys® Anti-SARS-CoV-2 S antibody test is for the qualitative and semi-quantitative detection of total antibodies (IgG, IgA and IgM) to SARS-CoV-2 in serum from individuals with prior COVID-19 infection and is intended to aid in identification of patients with an adaptive immune response to SARS-CoV-2 indicating prior infection to the SARS-CoV-2 virus. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for this test.

Click Here to learn more.

The American Medical Association makes updates to the Current Procedural Terminology (CPT) codes each year. Effective January 1, 2021, there will be CPT code changes for laboratory tests and/or components of tests provided by PathGroup.

Click here to learn more.

Effective October 1, 2020, the 2021 ICD-10-CM updates for patient encounters occurring October 1, 2020 through September 30, 2021 went into effect.

Click here to learn more.

Effective September 23, 2020, PathGroup will discontinue the use of test Phospholipase A2 Receptor Antibodies and replace it with Phospholipase A2 Receptor Antibody, IgG (Test Code: PLA2R).

Click here to learn more.

Effective immediately, PathGroup will discontinue Cystine, Urine Random (Test Code: CYSTE) and replace it with Cystine (Quantitative), 24 Hour Urine (Test CodeL CYSQTU).

Click here to learn more.

Effective June 12, 2020, PathGroup will include additional report interpretation information for results <10,000CFU/ml for urine cultures (Test Code: CXURN) and for cultures performed after a reflex from urinalysis (Test Code: UA2CX).

Click here for more information.

Effective immediately, new components will be added to the Autoimmune Liver Disease Reflexive Panel (Test Code: AILD) which will result in additional billed CPT codes.

Click here for more information.

Effective May 27, 2020, PathGroup is pleased to announce the availability of a new serologic test for human antibodies to SARS-Cov-2, the viral pathogen associated with COVID-19 (PathGroup Test Code: COVIDAB). On May 3, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Roche Elecsys® SARS-CoV-2 antibody test. The test is for the qualitative detection of total antibodies (including IgG, IgA and IgM) to SARS-CoV-2 in serum from individuals with prior COVID-19 infection. This test may aid in identification of patients with an adaptive immune response to SARS‑CoV‑2, indicating recent or prior infection to the SARS-CoV-2 virus.

Click Here to for more information.

Effective May 18, 2020, PathGroup will accept nasal (anterior nares) specimen collection for the SARS-CoV-2, RNA test (PathGroup Test Code: COVID19) when collected with the Hologic® Aptima® Multitest Swab Specimen Collection Kit.

Click Here for more information.

Effective June 8, 2020, the following Ova/Parasite tests will change specimen collection containers. For all Ova/Parasite orders placed on or after June 8, Total-Fix collection vials are required for the collection of stool needed for testing. All previous specimen containers will be discontinued. There will be no change in billed CPT codes.

Click here for more information.